10 results match your criteria: "Alexandra Regional General Hospital[Affiliation]"
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.
Ann Oncol
December 2024
Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Washington, USA.
Background: Belzutifan is a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor approved at a dose of 120 mg once daily for certain adults with VHL disease and adults with advanced renal cell carcinoma (RCC) following therapy with a programmed cell death protein 1 (PD-1) [or programmed death ligand 1 (PD-L1)] inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor. However, whether the belzutifan dose could be optimized is unclear.
Patients And Methods: The phase II LITESPARK-013 study (NCT04489771) enrolled patients with advanced clear cell RCC whose disease progressed after one to three prior systemic therapies, including an anti-PD-(L)1 regimen.
Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing.
Cancer Genomics Proteomics
November 2023
Genekor Medical S.A, Athens, Greece.
Background/aim: Germline copy number variation (CNV) is a type of genetic variant that predisposes significantly to inherited cancers. Today, next-generation sequencing (NGS) technologies have contributed to multi gene panel analysis in clinical practice.
Materials And Methods: A total of 2,163 patients were screened for cancer susceptibility, using a solution-based capture method.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
July 2022
From the Memorial Sloan Kettering Cancer Center, New York (S.M.); Institut du Cancer de Montpellier, Université Montpellier, INSERM Unité 1194, Montpellier (W.J.), and Institut Curie, Université Paris Cité, Paris (J.-Y.P.) - both in France; Kanagawa Cancer Center, Yokohama (T.Y.), Kyushu Cancer Center, National Hospital Organization, Fukuoka (E.T.), Showa University Hospital, Tokyo (J.T.), and Tokai University School of Medicine, Isehara-shi (N.N.) - all in Japan; Yonsei Cancer Center, Yonsei University Health System (J. Sohn), Samsung Medical Center (Y.H.P.), Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University (S.-A.I.), and Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Seoul, Kyungpook National University Chilgok Hospital, Daegu (Y.S.C.), and the National Cancer Center, Goyang-si (K.S.L.) - all in South Korea; the Department of Medical Oncology, Hospital Clínic de Barcelona (M.V., A.P.), Translational Genomics and Targeted Therapies in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (A.P.), the Department of Medicine, University of Barcelona (A.P.), the Breast Cancer Unit, Institute of Oncology (IOB)-Quirón Salud (A.P.), Institut Catala d'Oncologia l'Hospitalet-Hospital Duran i Reynals (M.G.-G.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (C.S.) - all in Barcelona; the University of Texas M.D. Anderson Cancer Center, Houston (N.T.U.); Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (B.X.), Zhejiang Cancer Hospital, Hangzhou (X.W.), the First Hospital of Jilin University, Changchun (W.L.), Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou (Q.L.), West China Hospital, Sichuan University, Chengdu (T.L.), and Liaoning Cancer Hospital and Institute, Shenyang (T.S.) - all in China; the Cleveland Clinic Foundation, Cleveland (H.C.F.M.); the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Rabin Medical Center, Petah Tikva, Tel Aviv University, Tel Aviv, Israel (R.Y.); Alexandra Regional General Hospital, Athens (F.Z.); Institut Jules Bordet, Brussels (A.G.); Queen Mary University of London, London (P.S.), and Edinburgh Cancer Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh (D.A.C.) - both in the United Kingdom; Daiichi Sankyo, Basking Ridge, NJ (D.G., L.Y., Y.W., J. Singh, P.V., G.M.); and the Breast Center, Department of Obstetrics and Gynecology, and Comprehensive Cancer Center Munich, Ludwig Maximilian University Hospital, Munich, Germany (N.H.).
Article Synopsis
- A study was conducted on patients with "HER2-low" metastatic breast cancer, which means they have low levels of HER2 that could potentially be treated, but existing therapies were not effective.
- In the trial, patients were randomly assigned to receive either trastuzumab deruxtecan or standard chemotherapy after having one or two previous treatments; the main goal was to measure how long patients remained free from disease progression.
- Results showed that those treated with trastuzumab deruxtecan had significantly longer progression-free survival (10.1 months vs. 5.4 months) and overall survival (23.9 months vs. 17.5 months) compared to the standard chemotherapy group, despite a high rate of serious adverse
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
J Crohns Colitis
October 2021
Evangelismos Hospital, Athens, Greece.
Background And Aims: This study aimed to compare real-world clinical effectiveness and safety of vedolizumab, an α4β7-integrin inhibitor, and anti-tumour necrosis factor-α [anti-TNFα] agents in biologic-naïve ulcerative colitis [UC] and Crohn's disease [CD] patients.
Methods: This was a 24-month retrospective medical chart study in adult UC and CD patients treated with vedolizumab or anti-TNFα in Canada, Greece and the USA. Inverse probability weighting was used to account for differences between groups.
Early Effect of Supplemented Infant Formulae on Intestinal Biomarkers and Microbiota: A Randomized Clinical Trial.
Nutrients
May 2020
Department of Neonatology, University Hospital Croix Rousse, Hospices Civils de Lyon, 69317 Lyon France.
Background: Post-natal gut maturation in infants interrelates maturation of the morphology, digestive, and immunological functions and gut microbiota development. Here, we explored both microbiota development and markers of gut barrier and maturation in healthy term infants during their early life to assess the interconnection of gut functions during different infant formulae regimes.
Methods: A total of 203 infants were enrolled in this randomized double-blind controlled trial including a breastfed reference group.
The impact of oral glutamine supplementation on the intestinal permeability and incidence of necrotizing enterocolitis/septicemia in premature neonates.
J Matern Fetal Neonatal Med
October 2011
Department of Neonatology, Alexandra Regional General Hospital, Athens, Greece.
Objective: To examine the impact of oral glutamine (Gln) supplementation on gut integrity and on the incidence of necrotizing enterocolitis (NEC)/septicemia of premature neonates.
Methods: Preterm neonates (n = 101, gestational age <34 weeks, birth weight <2000 g) were randomly allocated to receive from day 3 to day 30 postpartum, either oral Gln (0.3 g/kg/day, n = 51-Gln group) or placebo (caloreen-isocaloric, n = 50-control group).
Takayasu arteritis in pregnancy: safe management options in antenatal care. Case report.
Fetal Diagn Ther
December 2007
1st Department of Obstetrics and Gynecology, Alexandra Regional General Hospital, University of Athens, Athens, Greece.
Article Synopsis
- Takayasu arteritis is a chronic inflammatory vascular disease that typically affects women during their child-bearing years, primarily targeting the branches of the aortic arch.
- Pregnant patients often have pre-existing diagnoses and require careful management based on their disease state at the beginning of pregnancy, as complications like early-onset hypertension can arise.
- While vaginal delivery is preferred with continuous fetal monitoring, the postpartum period is generally uncomplicated despite some circulatory changes.
The effect of a prebiotic supplemented formula on growth and stool microbiology of term infants.
Early Hum Dev
January 2008
Department of Neonatal Medicine, Alexandra Regional General Hospital, Athens, Greece.
Background: The intestinal flora of breast-fed infants is generally dominated by bifidobacteria which have beneficial properties. Their presence is due to various compounds of breast milk including prebiotic substances.
Aim: This prospective, double blind, study compared the growth, acceptability and the proportion of bifidobacteria and clostridia in the stool flora of bottle-fed infants randomized to receive a formula with a specific mixture of 0.
The effect of a bifidobacter supplemented bovine milk on intestinal permeability of preterm infants.
Early Hum Dev
September 2007
Department of Neonatal Medicine, Alexandra Regional General Hospital, Athens, Greece.
Background: Preterm infants have increased intestinal permeability which can render them susceptible to infections from enterobacteriae.
Objectives: The primary objective was to investigate whether probiotic administration to preterm infants decreases intestinal permeability. Secondary outcomes studied were: somatic growth, tolerance, rates of sepsis and necrotizing enterocolitis.
The effect of a fructo-oligosaccharide supplemented formula on gut flora of preterm infants.
Early Hum Dev
May 2007
Department of Neonatal Medicine, Alexandra Regional General Hospital, Athens, Greece.
Aim: The intestinal flora of breast-fed infants is generally dominated by bifidobacteria which have beneficial properties. Their presence is due to various components of breast milk, including prebiotic substances. This prospective double-blind study compared the numbers of bifidobacteria in the stool flora of bottle-fed preterm infants randomized to receive for 14 days either a formula with prebiotic fructo-oligosaccharides at a concentration of 0.
View Article and Find Full Text PDF